Table 3.
Associations between angiopoietin quartiles and heart failure
| Angiopoietins | Number of Events (%) | Mean (95% CI) Event Rate per 1000 PY | Unadjusted HR (95% CI) | Model 1: Adjusted HR (95% CI) | Model 2: Adjusted HR (95% CI) | Model 3: Adjusted HR (95% CI) | Model 4: Adjusted HR (95% CI) |
|---|---|---|---|---|---|---|---|
| Participants with AKI | |||||||
| Angpt-1 | |||||||
| Log2-transformed | 134/746 (18%) | 44.6 (37.7 to 52.9) | 0.84 (0.76 to 0.93) | 0.73 (0.62 to 0.86) | 0.77 (0.65 to 0.91) | 0.78 (0.66 to 0.92) | 0.8 (0.67 to 0.95) |
| 1st quartile | 46/189 (24%) | 61.4 (46 to 82) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| 2nd quartile | 40/197 (20%) | 51.7 (37.9 to 70.5) | 0.85 (0.55 to 1.31) | 0.77 (0.45 to 1.33) | 0.87 (0.49 to 1.54) | 0.95 (0.53 to 1.7) | 0.9 (0.5 to 1.6) |
| 3rd quartile | 27/195 (14%) | 33.5 (23 to 48.8) | 0.54 (0.33 to 0.87) | 0.37 (0.19 to 0.72) | 0.39 (0.2 to 0.79) | 0.39 (0.2 to 0.79) | 0.44 (0.21 to 0.89) |
| 4th quartile | 21/165 (13%) | 31.2 (20.3 to 47.8) | 0.5 (0.3 to 0.86) | 0.29 (0.14 to 0.6) | 0.35 (0.16 to 0.74) | 0.38 (0.18 to 0.82) | 0.4 (0.18 to 0.87) |
| Angpt-2 | |||||||
| Log2-transformed | 134/746 (18%) | 44.6 (37.7 to 52.9) | 2.42 (2.03 to 2.88) | 2.4 (1.95 to 2.96) | 2.19 (1.73 to 2.78) | 2.16 (1.71 to 2.73) | 2.42 (1.78 to 3.29) |
| 1st quartile | 6/146 (4%) | 8.8 (3.9 to 19.5) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| 2nd quartile | 18/171 (11%) | 22.9 (14.4 to 36.3) | 2.63 (1.03 to 6.71) | 2.44 (0.92 to 6.43) | 2.59 (0.9 to 7.45) | 2.41 (0.84 to 6.94) | 2.53 (0.87 to 7.35) |
| 3rd quartile | 30/195 (15%) | 37.3 (26.1 to 53.4) | 4.37 (1.79 to 10.66) | 3.56 (1.4 to 9.04) | 3.6 (1.3 to 9.95) | 3.28 (1.19 to 9.1) | 3.49 (1.23 to 9.86) |
| 4th quartile | 80/234 (34%) | 109.9 (88.2 to 136.8) | 13.22 (5.67 to 30.8) | 10.17 (4.12 to 25.13) | 9.35 (3.45 to 25.39) | 8.8 (3.24 to 23.87) | 8.63 (2.95 to 25.28) |
| Angpt-1:Angpt-2 ratio | |||||||
| Log2-transformed | 134/746 (18%) | 44.6 (37.7 to 52.9) | 0.7 (0.64 to 0.76) | 0.61 (0.54 to 0.69) | 0.66 (0.57 to 0.75) | 0.68 (0.58 to 0.79) | |
| 1st quartile | 65/213 (31%) | 88 (69 to 112.3) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | |
| 2nd quartile | 38/199 (19%) | 46.4 (33.8 to 63.7) | 0.51 (0.34 to 0.78) | 0.37 (0.22 to 0.62) | 0.41 (0.23 to 0.71) | 0.43 (0.25 to 0.76) | |
| 3rd quartile | 24/174 (14%) | 32.7 (21.9 to 48.8) | 0.36 (0.22 to 0.58) | 0.23 (0.12 to 0.43) | 0.32 (0.16 to 0.61) | 0.36 (0.18 to 0.72) | |
| 4th quartile | 7/160 (4%) | 9.8 (4.7 to 20.6) | 0.11 (0.05 to 0.24) | 0.06 (0.02 to 0.15) | 0.09 (0.03 to 0.23) | 0.11 (0.04 to 0.32) | |
| Participants without AKI | |||||||
| Angpt-1 | |||||||
| Log2-transformed | 77/757 (10%) | 22.3 (17.9 to 27.9) | 1.03 (0.89 to 1.19) | 0.96 (0.79 to 1.16) | 1.01 (0.81 to 1.26) | 1.02 (0.82 to 1.27) | 1.04 (0.82 to 1.31) |
| 1st quartile | 14/186 (8%) | 15.7 (9.3 to 26.5) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| 2nd quartile | 27/179 (15%) | 34 (23.3 to 49.6) | 2.17 (1.13 to 4.15) | 1.99 (0.96 to 4.15) | 2.95 (1.28 to 6.76) | 1.91 (0.9 to 4.05) | 2.99 (1.29 to 6.93) |
| 3rd quartile | 18/181 (10%) | 22.5 (14.2 to 35.8) | 1.44 (0.71 to 2.92) | 0.94 (0.4 to 2.17) | 1.47 (0.58 to 3.78) | 0.91 (0.39 to 2.13) | 1.48 (0.57 to 3.87) |
| 4th quartile | 18/211 (9%) | 18.7 (11.8 to 29.6) | 1.2 (0.59 to 2.42) | 0.82 (0.33 to 2.02) | 1.17 (0.43 to 3.2) | 0.8 (0.32 to 1.97) | 1.24 (0.43 to 3.61) |
| Angpt-2 | |||||||
| Log2-transformed | 77/757 (10%) | 22.3 (17.9 to 27.9) | 2.61 (2.02 to 3.37) | 2.48 (1.83 to 3.36) | 1.57 (1.07 to 2.3) | 1.58 (1.08 to 2.32) | 1.66 (1.02 to 2.69) |
| 1st quartile | 9/229 (4%) | 8.1 (4.2 to 15.5) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| 2nd quartile | 15/205 (7%) | 14.9 (9 to 24.7) | 1.84 (0.79 to 4.28) | 1.25 (0.51 to 3.1) | 1.22 (0.48 to 3.12) | 1.23 (0.5 to 3.04) | 1.25 (0.49 to 3.22) |
| 3rd quartile | 22/181 (12%) | 28.5 (18.7 to 43.2) | 3.63 (1.63 to 8.06) | 2.08 (0.86 to 5.01) | 1.85 (0.75 to 4.6) | 2.11 (0.88 to 5.1) | 1.95 (0.75 to 5.07) |
| 4th quartile | 31/142 (22%) | 56.1 (39.5 to 79.8) | 7.7 (3.56 to 16.65) | 5.49 (2.34 to 12.86) | 2.72 (1.06 to 6.98) | 5.45 (2.33 to 12.8) | 2.95 (1.02 to 8.55) |
| Angpt-1:Angpt-2 ratio | |||||||
| Log2-transformed | 77/757 (10%) | 22.3 (17.9 to 27.9) | 0.83 (0.73 to 0.93) | 0.76 (0.65 to 0.89) | 0.91 (0.76 to 1.09) | 0.94 (0.77 to 1.14) | |
| 1st quartile | 24/162 (15%) | 34.5 (23.1 to 51.5) | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) | |
| 2nd quartile | 23/177 (13%) | 27.9 (18.6 to 42) | 0.79 (0.44 to 1.43) | 0.69 (0.35 to 1.34) | 1.08 (0.51 to 2.27) | 1.1 (0.51 to 2.34) | |
| 3rd quartile | 15/202 (7%) | 16.1 (9.7 to 26.6) | 0.45 (0.23 to 0.88) | 0.28 (0.13 to 0.6) | 0.38 (0.16 to 0.9) | 0.4 (0.17 to 0.97) | |
| 4th quartile | 15/216 (7%) | 15 (9.1 to 24.9) | 0.42 (0.22 to 0.82) | 0.29 (0.12 to 0.69) | 0.5 (0.19 to 1.32) | 0.54 (0.19 to 1.52) | |
Model 1: adjusted for race, sex, age, BMI, smoking status, history of COPD, diabetes, CVD, CKD, sepsis during hospitalization, 3-month eGFR, 3-month UACR, 3-month CRP, and clinical site. Model 2: Model 1 plus NT-proBNP and troponin. Model 3: Model 2 plus Angpt-2 (for the exposure variable Angpt-1) and Angpt-1 (for the exposure variable Angpt-2). Model 4: Model 2 plus baseline angiopoietin levels. PY, patient-year; ref, reference.